Comparative Pharmacology
Head-to-head clinical analysis: ETRAFON 2 25 versus INAPSINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETRAFON 2 25 versus INAPSINE.
ETRAFON 2-25 vs INAPSINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of perphenazine (a typical antipsychotic) and amitriptyline (a tricyclic antidepressant). Perphenazine blocks postsynaptic dopamine D2 receptors in the mesolimbic system, also antagonizes alpha-adrenergic, histaminergic, and muscarinic receptors. Amitriptyline inhibits reuptake of serotonin and norepinephrine at the presynaptic neuronal membrane, enhancing serotonergic and noradrenergic neurotransmission.
Butyrophenone antipsychotic; antagonizes dopamine D2 receptors in the CNS, also exhibits alpha-adrenergic blocking activity.
One tablet (2 mg perphenazine, 25 mg amitriptyline) orally three or four times daily. Maintenance: 2-4 tablets daily.
IM: 2.5-10 mg every 3-4 hours as needed; IV: 2.5-10 mg slow IV push (over 2-3 minutes), repeat every 30-60 minutes as needed; maximum total dose 20 mg.
None Documented
None Documented
Perphenazine: 8-12 hours (terminal); amitriptyline: 15-24 hours (terminal), with nortriptyline active metabolite half-life 18-44 hours. Steady-state achieved in 4-7 days.
Terminal elimination half-life is 10-22 hours (mean 14.5 hours) in adults; may be prolonged in elderly or patients with hepatic impairment.
Renal: approximately 25-50% as metabolites and unchanged drug; biliary/fecal: 10-25% as metabolites; the remainder is extensively metabolized via hepatic pathways.
Primarily renal (50-70% as unchanged drug and metabolites); biliary/fecal excretion accounts for approximately 20-30%.
Category C
Category C
Antipsychotic/Antidepressant Combination
Antipsychotic